Cytomegalovirus IgG-(CSF), in Visit Clinic

A negative cytomegalovirus (CMV) IgG test means no detectable IgG antibodies, suggesting you have not had prior CMV infection and are likely susceptible to primary infection. It may also reflect testing during the early “window” before antibodies form, so repeat testing or checking IgM can clarify recent exposure. In pregnancy or immunocompromise, follow-up and specialist advice are recommended.

A positive CMV IgG means past exposure or established immunity; it indicates the virus has infected you previously and that you have antibodies. CMV typically becomes latent and a positive IgG alone does not prove active infection. Pregnant women with IgG generally have lower risk of primary congenital CMV, though reactivation/reinfection is possible. Follow-up (IgM, avidity, PCR) is used if recent or active infection is suspected.

CMV negative means no evidence of past cytomegalovirus infection (no CMV antibodies). That’s generally favorable—especially for pregnant women and transplant recipients—because it lowers immediate risk of congenital or transplant-related CMV disease. However, CMV-negative people lack immunity and can catch a primary infection, which can be serious in pregnancy or when immunocompromised. Practice good hygiene and discuss preventive steps or testing with a clinician.

CMV detected in CSF (CMV encephalitis/meningitis) is treated with intravenous ganciclovir as first-line; foscarnet is used for ganciclovir‑resistant or intolerant cases. Therapy is continued until clinical improvement and negative CSF PCR, often for several weeks. Supportive care and immune restoration (e.g., start/optimize antiretroviral therapy in HIV) are essential. Monitor blood counts and renal function; consider oral valganciclovir for step-down.

Cytomegalovirus (CMV) is common and usually causes mild or no symptoms in healthy people. It can be serious for unborn babies (congenital CMV causes hearing loss, developmental delays) and for people with weakened immune systems, causing severe organ disease. Diagnosis uses blood or urine tests; antivirals are used for severe cases. Good hygiene and pregnancy precautions reduce transmission risk.

A CMV-negative component is a blood product from a donor who tests negative for cytomegalovirus antibodies; it’s used to prevent transfusion-transmitted CMV infection. These components are recommended for neonates, pregnant women, hematopoietic stem cell and solid-organ transplant recipients, and other severely immunocompromised patients. Leukoreduction further lowers CMV risk and may be used instead of or alongside CMV-negative products.